Erythromycin ethyl succinate

규격

1264-62-6CAS 번호

215-033-8EC 번호

4-O-[(2S,3R,4S,6R)-4-(dimethylamino)-2-[[(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-2,10-dioxo-oxacyclotetradec-6-yl]oxy]-6-methyloxan-3-yl] 1-O-eIUPAC 명칭

C43H75NO16화학식

862.1 g/mol분자량

erythromycin ethylsuccinate; 1264-62-6; Erythromycin ethyl succinate; Erythrocin ethyl succinate; anamycin; arpimycin; Wyamycin; ERY-PED; PEDIAMYCIN 400; Erythromycin, ethyl succinate; Erythromycin 2'-(ethyl butanedioate); Esinol; DTXSID4022993; Erythromycin, mono(ethyl succinate); NSC-756758; ERYLIQUID; REFKAS; 1014KSJ86F; Erythromycin, mono(ethyl succinate) (ester); Succinic acid, monoethyl ester, monoester with erythromycin; E.E.S 200; E.E.S 400; 41342-53-4; DTXCID902993; 4-O-[(2S,3R,4S,6R)-4-(dimethylamino)-2-[[(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-2,10-dioxo-oxacyclotetradec-6-yl]oxy]-6-methyloxan-3-yl] 1-O-ethyl butanedioate; CHEBI:31555; Eyrthromycin Ethyl Succinate; Erythroden; Erymin; Erythroped fte; Erythroped pi; Erythroped sf; Erythroped a; Erythroped pi sf; Erythroped fte sf; 4-O-((2S,3R,4S,6R)-4-(dimethylamino)-2-(((3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-14-ethyl-7,12,13-trihydroxy-4-((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl)oxy-3,5,7,9,11,13-hexamethyl-2,10-dioxo-oxacyclotetradec-6-yl)oxy)-6-methyloxan-3-yl) 1-O-ethyl butanedioate; E.E.S. 200; E.E.S. 400; Rommix 125; RefChem:55126; erythromycini ethylsuccinas; Ethylsuccinate, Erythromycin; Ethyl Succinate, Eyrthromycin; Succinate, Eyrthromycin Ethyl; (2R,3S,4S,5R,6R,8R,10R,11R,12S,13R)-5-(3,4,6-Trideoxy-2-O-(3-ethoxycarbonylpropanoyl)-3-dimethylamino-beta-D-xylo-hexopyranosyloxy)-3-(2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyloxy)-6,11,12-trihydroxy-2,4,6,8,10,12-hexamethyl-9-oxopentadecan-13-olide; 215-033-8; Eritrocina; Primacine; Pediamycin; Erythroped; EryPed; Wyamycin E; E.E.S.; MLS001074901; C43H75NO16; MFCD00084692; SMR000058868; Erythromycin 2'-(ethyl succinate); EES Granules; E.E.S; O4-[(2S,3R,4S,6R)-4-(dimethylamino)-2-[[(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydropyran-2-yl]oxy-3,5,7,9,11,13-hexamethyl-2,10-dioxo-oxacyclotetradec-6-yl]oxy]-6-methyl-tetrahydropyran-3-yl] O1-ethyl butanedioate; EES (Antiobiotic); HSDB 3075; Erythromycin ethylsuccinate [JAN]; EINECS 215-033-8; BRN 0077638; UNII-1014KSJ86F; NCGC00183038-01; E-Mycin-E; Eryped (TN); DURAPAEDIAT; Erythrocin W (TN); Erythromycin ethylsuccinate [USP:JAN]; Spectrum_001046; Spectrum2_000983; Spectrum3_000419; Spectrum4_000536; Spectrum5_000668; erythromycin-ethylsuccinate; Erythromycin-ethyl succinate; SCHEMBL18259; BSPBio_001978; KBioGR_001171; KBioSS_001526; 4-18-00-07416 (Beilstein Handbook Reference); MLS000028651; MLS001076672; DivK1c_000764; Erythromycin ethylsuccinate RS; SPECTRUM1500279; SPBio_001045; Erythromycin ethylsuccinate CRS; cid_443953; orb1226642; orb1310577; CHEMBL1200688; BDBM96262; E.E.S. (TN); HMS502G06; KBio1_000764; KBio2_001526; KBio2_004094; KBio2_006662; KBio3_001198; NINDS_000764; Sterile erythromycin ethylsuccinate; GLXC-07736; HMS1923I21; HMS2091D03; Pharmakon1600-01500279; HY-B0957; 2'-(Ethyl butanedioate)erythromycin; Tox21_113497; CCG-40201; LMPK05000001; MSK158695; NSC756758; s4060; AKOS008145410; CS-4434; MSK158695-100A; NSC 756758; Erythromycin ethylsuccinate (JP18/USP); ERYTHROMYCIN ETHYLSUCCINATE [MI]; IDI1_000764; ERYTHROMYCIN (AS ETHYL SUCCINATE); NCGC00021382-03; ERYTHROMYCIN ETHYLSUCCINATE [HSDB]; FE170906; CAS-1264-62-6; ERYTHROMYCIN ETHYLSUCCINATE [VANDF]; SBI-0051367.P003; ERYTHROMYCIN ETHYLSUCCINATE [USP-RS]; ERYTHROMYCIN ETHYLSUCCINATE [WHO-DD]; ERYTHROMYCIN ETHYLSUCCINATE [WHO-IP]; E6995; ERYTHROMYCIN ETHYL SUCCINATE [MART.]; D01361; AB00051980_11; AB00051980_12; ERYTHROMYCIN ETHYLSUCCINATE [ORANGE BOOK]; ERYTHROMYCIN ETHYLSUCCINATE [EP MONOGRAPH]; ERYTHROMYCIN ETHYLSUCCINATE [USP MONOGRAPH]; ERYTHROMYCINI ETHYLSUCCINAS [WHO-IP LATIN]; SR-05000001617; ERYZOLE COMPONENT ERYTHROMYCIN ETHYLSUCCINATE; SR-05000001617-1; BRD-K51677086-001-12-0; BRD-K51677086-001-13-8; PEDIAZOLE COMPONENT ERYTHROMYCIN ETHYLSUCCINATE; Q27114406; Z608353986; STERILE ERYTHROMYCIN ETHYLSUCCINATE [USP MONOGRAPH]; Erythromycin ethylsuccinate for impurity P identification CRS; Erythromycin ethylsuccinate Solution in Acetonitrile, 100ug/mL; (2S,3R,4S,6R)-4-(dimethylamino)-2-(((3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-14-ethyl-7,12,13-trihydroxy-4-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3,5,7,9,11,13-hexamethyl-2,10-dioxooxacyclotetradecan-6-yl)oxy)-6-methyltetrahydro-2H-pyran-3-yl ethyl succinate; (2S,3R,4S,6R)-4-(Dimethylamino)-2-{[(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy}-3,5,7,9,11,13-hexamethyl-2,10-dioxo-1-oxacyclotetradecan-6-yl]oxy}-6-methyloxan-3-yl ethyl butanedioate; (3R*,4S*,5S*,6R*,7R*,9R*,11R*,12R*,13S*,14R*)-4-((2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-((2- ethyl butanedioate -3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)oxacyclotetradecane-2,10-dione동의어